Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho

In the Viral Load Cohort North-East Lesotho (VICONEL) human immunodeficiency virus cohort, 14 242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021. Rates of viral suppression to <50 copies/mL were 84.8%, 93.9%, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tschumi, Nadine, Lerotholi, Malebanye, Motaboli, Lipontso, Mokete, Moliehi, Labhardt, Niklaus D, Brown, Jennifer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640687/
https://www.ncbi.nlm.nih.gov/pubmed/37358226
http://dx.doi.org/10.1093/cid/ciad390
_version_ 1785146656302301184
author Tschumi, Nadine
Lerotholi, Malebanye
Motaboli, Lipontso
Mokete, Moliehi
Labhardt, Niklaus D
Brown, Jennifer A
author_facet Tschumi, Nadine
Lerotholi, Malebanye
Motaboli, Lipontso
Mokete, Moliehi
Labhardt, Niklaus D
Brown, Jennifer A
author_sort Tschumi, Nadine
collection PubMed
description In the Viral Load Cohort North-East Lesotho (VICONEL) human immunodeficiency virus cohort, 14 242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021. Rates of viral suppression to <50 copies/mL were 84.8%, 93.9%, and 95.4% before, 12 months after, and 24 months after transition, respectively. Sex, age, pretransition viral load, and treatment backbone correlated with 24-month viremia.
format Online
Article
Text
id pubmed-10640687
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106406872023-11-14 Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho Tschumi, Nadine Lerotholi, Malebanye Motaboli, Lipontso Mokete, Moliehi Labhardt, Niklaus D Brown, Jennifer A Clin Infect Dis Brief Report In the Viral Load Cohort North-East Lesotho (VICONEL) human immunodeficiency virus cohort, 14 242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021. Rates of viral suppression to <50 copies/mL were 84.8%, 93.9%, and 95.4% before, 12 months after, and 24 months after transition, respectively. Sex, age, pretransition viral load, and treatment backbone correlated with 24-month viremia. Oxford University Press 2023-06-26 /pmc/articles/PMC10640687/ /pubmed/37358226 http://dx.doi.org/10.1093/cid/ciad390 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Tschumi, Nadine
Lerotholi, Malebanye
Motaboli, Lipontso
Mokete, Moliehi
Labhardt, Niklaus D
Brown, Jennifer A
Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
title Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
title_full Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
title_fullStr Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
title_full_unstemmed Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
title_short Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
title_sort two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the viconel human immunodeficiency virus cohort in lesotho
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640687/
https://www.ncbi.nlm.nih.gov/pubmed/37358226
http://dx.doi.org/10.1093/cid/ciad390
work_keys_str_mv AT tschuminadine twoyearoutcomesoftreatmentexperiencedadultsafterprogrammatictransitioningtodolutegravirlongitudinaldatafromtheviconelhumanimmunodeficiencyviruscohortinlesotho
AT lerotholimalebanye twoyearoutcomesoftreatmentexperiencedadultsafterprogrammatictransitioningtodolutegravirlongitudinaldatafromtheviconelhumanimmunodeficiencyviruscohortinlesotho
AT motabolilipontso twoyearoutcomesoftreatmentexperiencedadultsafterprogrammatictransitioningtodolutegravirlongitudinaldatafromtheviconelhumanimmunodeficiencyviruscohortinlesotho
AT moketemoliehi twoyearoutcomesoftreatmentexperiencedadultsafterprogrammatictransitioningtodolutegravirlongitudinaldatafromtheviconelhumanimmunodeficiencyviruscohortinlesotho
AT labhardtniklausd twoyearoutcomesoftreatmentexperiencedadultsafterprogrammatictransitioningtodolutegravirlongitudinaldatafromtheviconelhumanimmunodeficiencyviruscohortinlesotho
AT brownjennifera twoyearoutcomesoftreatmentexperiencedadultsafterprogrammatictransitioningtodolutegravirlongitudinaldatafromtheviconelhumanimmunodeficiencyviruscohortinlesotho

Ejemplares similares